<DOC>
	<DOCNO>NCT01386528</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe United States America ( USA ) . The aim trial evaluate safety efficacy NNC-0156-0000-0009 ( nonacog beta pegol ) surgical procedure patient haemophilia B .</brief_summary>
	<brief_title>Efficacy Safety NNC-0156-0000-0009 During Surgical Procedures Subjects With Haemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Patients haemophilia B FIX activity equal 2 % Male patient moderately severe severe congenital haemophilia B FIX activity equal 2 % accord medical record History least 150 exposure day FIX product Scheduled major surgery Known history FIX ( coagulation factor nine ) inhibitor base exist medical record , laboratory report review patient LAR ( legal acceptable representative ) interview Current FIX ( coagulation factor nine ) inhibitor equal 0.6 Bethesda Units ( central laboratory ) Previous arterial thrombotic event ( e.g . myocardial infarction intracranial thrombosis ) previous deep venous thrombosis pulmonary embolism ( define available medical record ) ALT ( alanine aminotransferase ) 3 time upper limit normal reference range screen ( central laboratory ) Immune modulate chemotherapeutic medication</criteria>
	<gender>Male</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>